CL2014000175A1 - Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. - Google Patents

Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Info

Publication number
CL2014000175A1
CL2014000175A1 CL2014000175A CL2014000175A CL2014000175A1 CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1 CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1
Authority
CL
Chile
Prior art keywords
oxo
compound
cancer
benzazepin
butanamide
Prior art date
Application number
CL2014000175A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014000175A1 publication Critical patent/CL2014000175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CL2014000175A 2011-07-27 2014-01-23 Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. CL2014000175A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
CL2014000175A1 true CL2014000175A1 (es) 2014-08-22

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000175A CL2014000175A1 (es) 2011-07-27 2014-01-23 Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Country Status (36)

Country Link
US (1) US8569286B2 (es)
EP (1) EP2736920B1 (es)
JP (1) JP6027110B2 (es)
KR (1) KR101578309B1 (es)
CN (1) CN103732612B (es)
AP (1) AP4080A (es)
AR (1) AR087107A1 (es)
AU (1) AU2012287251B2 (es)
BR (1) BR112014001600B1 (es)
CA (1) CA2841178C (es)
CL (1) CL2014000175A1 (es)
CO (1) CO6862159A2 (es)
CR (1) CR20140036A (es)
CY (1) CY1116645T1 (es)
DK (1) DK2736920T3 (es)
DO (1) DOP2014000011A (es)
EA (1) EA023044B1 (es)
EC (1) ECSP14013179A (es)
ES (1) ES2544937T3 (es)
GT (1) GT201400012A (es)
HK (1) HK1194086A1 (es)
HR (1) HRP20150771T1 (es)
HU (1) HUE027534T2 (es)
IL (1) IL229988A (es)
JO (1) JO3148B1 (es)
MA (1) MA35611B1 (es)
ME (1) ME02171B (es)
MX (1) MX356536B (es)
MY (1) MY184303A (es)
PE (1) PE20141061A1 (es)
PL (1) PL2736920T3 (es)
PT (1) PT2736920E (es)
RS (1) RS54135B1 (es)
SI (1) SI2736920T1 (es)
TW (1) TWI568730B (es)
WO (1) WO2013016081A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
AR105080A1 (es) * 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
MY196648A (en) 2016-02-05 2023-04-27 Denali Therapeutics Inc Inhibitors of Receptor-Interacting Protein Kinase 1
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6911047B2 (ja) * 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
KR102418766B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
KR102512899B1 (ko) * 2016-08-31 2023-03-23 일라이 릴리 앤드 캄파니 고형 종양의 치료를 위한 투약 요법
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
PT3552017T (pt) 2016-12-09 2022-05-04 Denali Therapeutics Inc Compostos úteis como inibidores de ripk1
IL268349B1 (en) 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
AU2018360800A1 (en) 2017-11-01 2020-05-14 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
EP3706754A1 (en) * 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
KR20210005714A (ko) * 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
CN114340611A (zh) 2019-04-08 2022-04-12 频率医疗公司 用于治疗听力损失的chir99021和丙戊酸的组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951466B1 (en) * 1996-12-23 2009-01-21 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
BRPI0407262A (pt) 2003-02-04 2006-01-31 Hoffmann La Roche Derivados de malonamida como inibidores gama-secretase
KR20070087233A (ko) 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
WO2005040126A1 (en) 2003-10-06 2005-05-06 F. Hoffman-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
CN101410378B (zh) 2006-03-27 2012-12-05 霍夫曼-拉罗奇有限公司 作为γ分泌酶抑制剂的丙二酰胺衍生物
CN101622232A (zh) * 2007-02-02 2010-01-06 弗·哈夫曼-拉罗切有限公司 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
ECSP14013179A (es) 2014-03-31
IL229988A (en) 2017-07-31
HUE027534T2 (en) 2016-11-28
PL2736920T3 (pl) 2015-11-30
US8569286B2 (en) 2013-10-29
EP2736920A1 (en) 2014-06-04
MY184303A (en) 2021-03-31
CN103732612B (zh) 2015-09-23
PE20141061A1 (es) 2014-09-06
US20130029972A1 (en) 2013-01-31
HK1194086A1 (en) 2014-10-10
CO6862159A2 (es) 2014-02-10
ES2544937T3 (es) 2015-09-07
KR20140026624A (ko) 2014-03-05
MA35611B1 (fr) 2014-11-01
JP6027110B2 (ja) 2016-11-16
BR112014001600B1 (pt) 2022-09-13
HRP20150771T1 (hr) 2015-08-28
CR20140036A (es) 2014-03-21
AU2012287251B2 (en) 2015-05-14
EA201490161A1 (ru) 2014-04-30
TWI568730B (zh) 2017-02-01
KR101578309B1 (ko) 2015-12-16
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
MX356536B (es) 2018-06-01
AR087107A1 (es) 2014-02-12
PT2736920E (pt) 2015-09-16
SI2736920T1 (sl) 2015-08-31
CN103732612A (zh) 2014-04-16
CA2841178C (en) 2016-12-20
NZ618891A (en) 2015-12-24
AP2014007362A0 (en) 2014-01-31
JO3148B1 (ar) 2017-09-20
TW201315732A (zh) 2013-04-16
DOP2014000011A (es) 2014-07-31
AP4080A (en) 2017-03-29
DK2736920T3 (en) 2015-07-20
GT201400012A (es) 2014-07-16
ME02171B (me) 2015-10-20
CY1116645T1 (el) 2017-03-15
EP2736920B1 (en) 2015-07-01
BR112014001600A2 (pt) 2017-02-21
AU2012287251A1 (en) 2014-01-30
WO2013016081A1 (en) 2013-01-31
MX2014001084A (es) 2014-02-27
JP2014527042A (ja) 2014-10-09
RS54135B1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
CL2014000175A1 (es) Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
CL2009000448A1 (es) Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MY177344A (en) Compounds and their methods of use
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
PH12015501609A1 (en) Phenicol antibacterials
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
PH12018500071A1 (en) Plinabulin compositions
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TW201613864A (en) Novel compounds
PH12015502118A1 (en) Pyridin-4-yl derivatives
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
WO2014153495A9 (en) Novel stat3 inhibitors
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2014115169A3 (en) Crizotinib solid dispersion
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors